DeepMatter inks deal with India pharma giant Dr. Reddy's

Digital chemistry technology company DeepMatter has signed a contract with generic pharmaceuticals giant Dr. Reddy's Laboratories, based in Hyderabad, India, for its ‘DigitalGlassware’ platform.

The AIM-traded firm said it would provide its DigitalGlassware platform to Dr. Reddy's process development team, for the development and scale-up of chemistry procedures to hand over to colleagues.

It said the collaboration was part of DeepMatter's ongoing strategy to provide its DigitalGlassware platform to major global contract research organisations (CROs), where the need for reproducibility was “paramount” in accelerating the discovery of new drugs.

“We are focused on creating value for the world's largest CROs with our DigitalGlassware platform,” said chief executive officer Mark Warne.

“We are working with them to firmly establish it as the go-to platform for capturing and structuring time-course sensor data in the lab, to enable improved insights for better productivity and discovery.”

Warne said Dr. Reddy's was “actively interested” in the capture of parameters that could be used for their process development and modelling activities.

“We are working with them to see how DigitalGlassware, with the use of sensor devices, can aid in the capture of these important parameters and facilitate analysis of runs performed at Dr. Reddy's.”

At 1537 BST, shares in DeepMatter were up 6.72% at 1.38p.